Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1

RNA Biology

Volumn 11, Issue 6, 2014, Pages

  Wojciechowska, Marzena ^a   Taylor, Katarzyna ^b   Sobczak, Krzysztof ^b   Napierala, Marek ^c   Krzyzosiak, Wlodzimierz J ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CUG foci; CUGBP1 protein; MBNL1 protein; Myotonic dystrophy; Protein kinases; Protein phosphorylation; RNA splicing; RNA binding proteins

Indexed keywords

C 16; C 51; MBNL1 PROTEIN; MESSENGER RNA PRECURSOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; UGBP1 PROTEIN; UNCLASSIFIED DRUG; CELF1 PROTEIN; CELF1 PROTEIN, HUMAN; ENZYME INHIBITOR; MBNL1 PROTEIN, HUMAN; MESSENGER RNA; PHOSPHOTRANSFERASE; PROTEIN BINDING; RNA BINDING PROTEIN; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MYOBLAST; MYOTONIC DYSTROPHY; PHENOTYPE; PROTEIN LOCALIZATION; STEADY STATE; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROTEIN TRANSPORT; RNA SPLICING;

ALTERNATIVE SPLICING; CELF1 PROTEIN; CELLS, CULTURED; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MYOBLASTS; MYOTONIC DYSTROPHY; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN TRANSPORT; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84906489197     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.28799     Document Type: Article

References (52)

1. Harper PS. Myotonic Dystrophy 3rd edn., (W.B. Saunders, London), 2001.
2. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276:7820-6; PMID:11124939; http://dx.doi.org/10.1074/jbc. M005960200
3. Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 2007; 117:2802-11; PMID:17823658; http://dx.doi.org/10.1172/JCI32308
4. Mankodi A, Lin X, Blaxall BC, Swanson MS, Thornton CA. Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res 2005; 97:1152-5; PMID:16254211; http://dx.doi.org/10.1161/01.RES.0000193598.89753.e3
5. Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003; 54:760-8; PMID:14681885; http://dx.doi.org/10.1002/ana.10763
6. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40-7; PMID:11528389; http://dx.doi.org/10.1038/ ng704
7. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280:737-41; PMID:9563950; http://dx.doi.org/10.1126/science.280.5364.737
8. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004; 13:3079-88; PMID:15496431; http://dx.doi.org/10.1093/hmg/ddh327
9. Hino S, Kondo S, Sekiya H, Saito A, Kanemoto S, Murakami T, Chihara K, Aoki Y, Nakamori M, Takahashi MP, et al. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum Mol Genet 2007; 16:2834-43; PMID:17728322; http://dx.doi.org/10.1093/hmg/ddm239
10. Timchenko NA, Wang GL, Timchenko LT. RNA CUG-binding protein 1 increases translation of 20-kDa isoform of CCAAT/enhancer-binding protein beta by interacting with the alpha and beta subunits of eukaryotic initiation translation factor 2. J Biol Chem 2005; 280:20549-57; PMID:15788409; http://dx.doi.org/10.1074/jbc.M409563200
11. Timchenko LT, Salisbury E, Wang GL, Nguyen H, Albrecht JH, Hershey JW, Timchenko NA. Age-specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver. J Biol Chem 2006; 281:32806-19; PMID:16931514; http://dx.doi.org/10.1074/jbc.M605701200
12. Wang ET, Cody NA, Jog S, Biancolella M, Wang TT, Treacy DJ, Luo S, Schroth GP, Housman DE, Reddy S, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 2012; 150:710-24; PMID:22901804; http://dx.doi.org/10.1016/j.cell.2012.06.041
13. Rau F, Freyermuth F, Fugier C, Villemin JP, Fischer MC, Jost B, Dembele D, Gourdon G, Nicole A, Duboc D, et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 2011; 18:840-5; PMID:21685920; http://dx.doi.org/10.1038/nsmb.2067
14. Fernandez-Costa JM, Garcia-Lopez A, Zuñiga S, Fernandez-Pedrosa V, Felipo-Benavent A, Mata M, Jaka O, Aiastui A, Hernandez-Torres F, Aguado B, et al. Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients. Hum Mol Genet 2013; 22:704-16; PMID:23139243; http://dx.doi.org/10.1093/hmg/dds478
15. Jin J, Wang GL, Salisbury E, Timchenko L, Timchenko NA. GSK3beta-cyclin D3-CUGBP1-eIF2 pathway in aging and in myotonic dystrophy. Cell Cycle 2009; 8:2356-9; PMID:19571675; http://dx.doi.org/10.4161/cc.8.15.9248
16. Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT. GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest 2012; 122:4461-72; PMID:23160194; http://dx.doi.org/10.1172/JCI64081
17. Salisbury E, Sakai K, Schoser B, Huichalaf C, Schneider-Gold C, Nguyen H, Wang GL, Albrecht JH, Timchenko LT. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res 2008; 314:2266-78; PMID:18570922; http://dx.doi.org/10. 1016/j.yexcr.2008.04.018
18. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007; 28:68-78; PMID:17936705; http://dx.doi.org/10.1016/j.molcel.2007. 07.027
19. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009; 119:3797-806; PMID:19907076; http://dx.doi.org/10.1172/JCI37976
20. Botta A, Malena A, Tibaldi E, Rocchi L, Loro E, Pena E, Cenci L, Ambrosi E, Bellocchi MC, Pagano MA, et al. MBNL142 and MBNL143 gene isoforms, overexpressed in DM1-patient muscle, encode for nuclear proteins interacting with Src family kinases. Cell Death Dis 2013; 4:e770; PMID:23949219; http://dx.doi.org/10.1038/cddis.2013.291
21. Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res 2012; 40:11-26; PMID:21908410; http://dx.doi.org/10.1093/nar/gkr729
22. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009; 325:336-9; PMID:19608921; http://dx.doi.org/10.1126/ science.1173110
23. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012; 488:111-5; PMID:22859208; http://dx.doi.org/10.1038/nature11362
24. Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 2009; 106:13915-20; PMID:19667189; http://dx.doi.org/10.1073/pnas.0905780106
25. González-Barriga A, Mulders SA, van de Giessen J, Hooijer JD, Bijl S, van Kessel ID, van Beers J, van Deutekom JC, Fransen JA, Wieringa B, et al. Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids 2013; 2:e81; PMID:23511335; http://dx.doi.org/10.1038/mtna.2013.9
26. Sobczak K, Wheeler TM, Wang W, Thornton CA. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther 2013; 21:380-7; PMID:23183533; http://dx.doi.org/10.1038/mt.2012.222
27. François V, Klein AF, Beley C, Jollet A, Lemercier C, Garcia L, Furling D. Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol 2011; 18:85-7; PMID:21186365; http://dx.doi.org/10.1038/nsmb.1958
28. Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, Thornton CA, Disney MD. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc 2009; 131:9767-79; PMID:19552411; http://dx.doi.org/10.1021/ja9020149
29. Arambula JF, Ramisetty SR, Baranger AM, Zimmerman SC. A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci U S A 2009; 106:16068-73; PMID:19805260; http://dx.doi.org/10.1073/pnas.0901824106
30. Childs-Disney JL, Hoskins J, Rzuczek SG, Thornton CA, Disney MD. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol 2012; 7:856-62; PMID:22332923; http://dx.doi.org/10.1021/cb200408a
31. Jahromi AH, Nguyen L, Fu Y, Miller KA, Baranger AM, Zimmerman SC. A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. ACS Chem Biol 2013; 8:1037-43; PMID:23480597; http://dx.doi.org/10.1021/cb400046u
32. Jahromi AH, Honda M, Zimmerman SC, Spies M. Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules. Nucleic Acids Res 2013; 41:6687-97; http://dx.doi.org/10.1093/nar/gkt330
33. Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A 2009; 106:18551-6; PMID:19822739; http://dx.doi.org/10.1073/pnas. 0903234106
34. Ketley A, Chen CZ, Li X, Arya S, Robinson TE, Granados-Riveron J, Udosen I, Morris GE, Holt I, Furling D, et al. High content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC independent pathway in Myotonic Dystrophy cell lines. Hum Mol Genet 2013; 23:1551-62; PMID:24179176; http://dx.doi.org/10.1093/hmg/ddt542
35. Jammi NV, Whitby LR, Beal PA. Small molecule inhibitors of the RNA-dependent protein kinase. Biochem Biophys Res Commun 2003; 308:50-7; PMID:12890478; http://dx.doi.org/10.1016/S0006-291X(03)01318-4
36. Bryk R, Wu K, Raimundo BC, Boardman PE, Chao P, Conn GL, Anderson E, Cole JL, Duffy NP, Nathan C, et al. Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett 2011; 21:4108-14; PMID:21632247; http://dx.doi.org/10.1016/j.bmcl.2011.04.149
37. Chen HM, Wang L, D'Mello SR. A chemical compound commonly used to inhibit PKR, 8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one, protects neurons by inhibiting cyclin-dependent kinase. Eur J Neurosci 2008; 28 : 2003-16; PMID:19046382; http://dx.doi.org/10.1111/j.1460-9568.2008.06491.x
38. Zhu PJ, Huang W, Kalikulov D, Yoo JW, Placzek AN, Stoica L, Zhou H, Bell JC, Friedlander MJ, Krnjević K, et al. Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ mediated disinhibition. Cell 2011; 147:1384-96; PMID:22153080; http://dx.doi.org/10.1016/ j.cell.2011.11.029
39. Shimazawa M, Hara H. Inhibitor of double stranded RNA-dependent protein kinase protects against cell damage induced by ER stress. Neurosci Lett 2006; 409:192-5; PMID:17055645; http://dx.doi.org/10.1016/j.neulet.2006.09.074
40. Shimazawa M, Ito Y, Inokuchi Y, Hara H. Involvement of double-stranded RNA-dependent protein kinase in ER stress-induced retinal neuron damage. Invest Ophthalmol Vis Sci 2007; 48:3729-36; PMID:17652745; http://dx.doi.org/10.1167/ iovs.06-1122
41. Page G, Rioux Bilan A, Ingrand S, Lafay-Chebassier C, Pain S, Perault Pochat MC, Bouras C, Bayer T, Hugon J. Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience 2006; 139:1343-54; PMID:16581193; http://dx.doi.org/10.1016/j.neuroscience. 2006.01.047
42. Ho TH, Bundman D, Armstrong DL, Cooper TA. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet 2005; 14:1539-47; PMID:15843400; http://dx.doi.org/10.1093/hmg/ddi162
43. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 2008; 105:20333-8; PMID:19075228; http://dx.doi.org/10.1073/pnas.0809045105
44. Masuda A, Andersen HS, Doktor TK, Okamoto T, Ito M, Andresen BS, Ohno K. CUGBP1 and MBNL1 preferentially bind to 3 2 UTRs and facilitate mRNA decay. Sci Rep 2012; 2:209; PMID:22355723; http://dx.doi.org/10.1038/srep00209
45. Sen S, Talukdar I, Webster NJ. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 2009; 29 : 871-80; PMID: 19047369; http://dx.doi.org/10.1128/MCB.01709-08
46. Wojciechowska M, Krzyzosiak WJ. Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 2011; 20:3811-21; PMID:21729883; http://dx.doi.org/10.1093/hmg/ddr299
47. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, Henderson D, Schalling M, Swanson MS, Thornton CA. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10:2165-70; PMID:11590133; http://dx.doi.org/10.1093/hmg/10.19.2165
48. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, Swanson MS, Thornton CA. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006; 15:2087-97; PMID:16717059; http://dx.doi.org/10.1093/hmg/ddl132
49. Yeo GW, Coufal NG, Liang TY, Peng GE, Fu XD, Gage FH. An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat Struct Mol Biol 2009; 16:130-7; PMID:19136955; http://dx.doi.org/10. 1038/nsmb.1545
50. Licatalosi DD, Yano M, Fak JJ, Mele A, Grabinski SE, Zhang C, Darnell RB. Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. Genes Dev 2012; 26:1626-42; PMID:22802532; http://dx.doi.org/10.1101/gad.191338.112
51. Pelletier R, Hamel F, Beaulieu D, Patry L, Haineault C, Tarnopolsky M, Schoser B, Puymirat J. Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis 2009; 36 :181-90; PMID:19632331; http://dx.doi.org/10.1016/j.nbd.2009.07.009
52. de Mezer M, Wojciechowska M, Napierala M, Sobczak K, Krzyzosiak WJ. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res 2011; 39:3852-63; PMID:21247881; http://dx.doi.org/10.1093/nar/gkq1323